Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (3486)	12/31/1997 2:27:00 AM
From: BriBear	Read Replies (1) \| Respond to of 6136

Thank you... a bit over my head (I majored in Computer Sci, not Biology) but still enlightening; I could still follow a lot from context. To sum up, am I correct in saying that all nucleoSide RT inhibitors must be metabolized (phosphorylated) into nucleoTide form before they are active? And that Adefovir, already being in nucleoTide form (or very similar), doesn't have to go thru this conversion? Is there any benefit to this? Do ALL (current) RT inhibitors (Side & Tide) eventually function the same way? Which, if I understand it correctly, is to mimic true nucleotides and, during transcription by RT reading the viral RNA, be attached to the viral DNA chain under construction and terminate it? And, since the RTI is an analogue & not the real thing, no further bases can be attached, therefore leaving an incomplete & presumably non-functional DNA strand?